| Literature DB >> 30703172 |
Tanveer Bashir1, Srinivas Murki1, Sai Kiran1, Venkat Kallem Reddy1, Tejo Pratap Oleti1.
Abstract
BACKGROUND: With increasing use of nCPAP, the safety and comfort associated with nCPAP have come into the forefront. The reported incidence of nasal injuries associated with the use of nCPAP is 20% to 60%. A recent meta-analysis concluded that the use of nasal masks significantly decreases CPAP failure and the incidence of moderate to severe nasal injury and stress the need for a well powered RCT to confirm their findings.Entities:
Mesh:
Year: 2019 PMID: 30703172 PMCID: PMC6355017 DOI: 10.1371/journal.pone.0211476
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Consort flow diagram of the study participants.
Fig 2Drager BabyFlow mask.
Fig 3Hudson short binasal prongs.
Fig 4Clinical trial protocol for titration, weaning and removal of CPAP.
Nasal injury assessment score chart[8,9].
| 0 = Normal | |
| 0 = Normal | |
| 0 = Normal | |
| 0 = Normal | |
| 0 = Normal | |
| 0 = Normal |
Nasal injury scoring:
0 = No injury, 1–4 = mild injury, 5–6 = moderate injury, ≥7 = severe injury
Baseline characteristics.
| Category | Subcategory | Prong continue group(no = 60) | Mask continue group(no = 57) | Rotation group(no = 58) | p- Value |
|---|---|---|---|---|---|
| Gestation Median (IQR) | 29(28–30) | 30(29–30) | 29(28–30) | 0.481 | |
| Birth weight (Kg)Mean ±SD | 1.06 ± 0.234 | 1.14 ± 0.206 | 1.12 ± 0.239 | 0.104 | |
| Male n (%) | 37(61.7) | 33(57.9) | 32(55.2) | 0.772 | |
| SGA (<10th Centile)n (%) | 10(16.7) | 6(10.5) | 5(8.6) | 0.371 | |
| Singleton n (%) | 43(71.7) | 40(70.2) | 38(65.5) | 0.601 | |
| Maternal Age (yrs) Mean ±SD | 29.03 ± 4.403 | 30.35 ± 6.004 | 29.36 ± 4.432 | 0.337 | |
| PPROM n (%) | 16(26.7) | 19(33.3) | 18(31.0) | 0.727 | |
| PIH n (%) | 21(35.0) | 21(36.8) | 14(24.1) | 0.285 | |
| Doppler compromise n (%) | 14(23.3) | 10(17.5) | 8(13.8) | 0.401 | |
| Antenatal Steroids | Partial n(%) | 14(23.3) | 6(10.5) | 16(27.6) | 0.117 |
| Complete n(%) | 46(76.7) | 49(86.0) | 41(70.7) | ||
| C-section n (%) | 47(78) | 47(82.5) | 42(72.4) | 0.429 | |
| RDS n (%) | 47(78.3) | 39(68.4) | 45(77.6) | 0.393 | |
| TTNB n (%) | 13(21.7) | 18(31.6) | 13(22.4) | 0.393 | |
| Pneumonia n (%) | 5(8.3) | 7(12.3) | 6(10.3) | 0.78 | |
| Age at randomization(minutes)Median (IQR) | 20(15–20) | 20(20–20) | 20(15–20) | 0.379 | |
| nCPAP at start Median (IQR) | 5(5–6) | 5(5–5) | 5(5–5) | 0.374 | |
| FIO2 at start Median (IQR) | 30(30–40) | 30(30–40) | 30(30–40) | 0.901 |
SD—Standard deviation, IQR Inter quartile range.
Values represented as mean (SD), median (IQR) or numbers (proportion); analysis by
b. ANOVA test,
a. Mann-Whitney U test,
c. Chi square test or Fisher’s Exact Test.
Primary nasal injury outcomes.
| Category | Subcategory | Prong continue group (no. 60) | Mask continue group (no. 57) | Rotation group (no. 58) | p- Value |
|---|---|---|---|---|---|
| Nasal injury n (%) | Any | 55(91.6) | 19(33.3) | 33(56.9) | <0.0001 |
| Mild | 33(55.0) | 19(33.3) | 30(51.7) | 0.042 | |
| Moderate | 14(23.3) | 0(0.0) | 3(5.2) | <0.0001 | |
| Severe | 8(13.3) | 0(0.0) | 0(0.0) | <0.0001 | |
| Moderate to severe nasal injury n (%) | 22(36.7) | 0(0.0) | 3(5.2) | <0.0001 | |
| Erythema n (%) | 39(65) | 19(33.3) | 32(55.2) | 0.002 | |
| Dilation of nares n (%) | 19(31.7) | 0(0.0) | 1(1.7) | <0.0001 | |
| Columella indentation/excoriation n (%) | 15(25) | 0(0.0) | 2(3.4) | <0.0001 | |
| Notching on bridge of nose | 0 | 0 | 0 | ||
| Altered shape of nose | 13(21.7) | 0(0.0) | 3(5.2) | <0.0001 | |
| indentation/excoriation/bleeding any other part of nose n (%) | 11(18.3) | 0(0.0) | 0(0.0) | <0.0001 | |
| Maximum Nasal Injury Score Median (IQR) | 3(2–5) | 0(0–1) | 1(0–2) | <0.0001 |
SD—Standard deviation, IQR Inter quartile range.
Values represented as mean (SD), median (IQR) or numbers (proportion);
Values represented as mean (SD), median (IQR) or numbers (proportion); analysis by
a. Mann-Whitney U test,
c. Chi square test or Fisher’s Exact Test.
Secondary outcomes.
| Category | Subcategory | Prong continue group (no = 60) | Mask continue group (no = 57) | Rotation group (no = 58) | p-Value |
|---|---|---|---|---|---|
| CPAP Hours Median (IQR) | 22.5(10.25–36) | 20(10–36) | 29.5(21.75–47.25) | 0.054 | |
| Oxygen (Days)Median (IQR) | 5(3–18) | 6(3–14) | 6(4–18) | 0.904 | |
| CPAP failure rate n (%) | 11(18.3) | 13(22.8) | 6(10.3) | 0.198 | |
| MV n (%) | Within 72 hours | 11(18.3) | 14(24.6) | 5(8.6) | 0.127 |
| 72 hours to 7 days | 8(13.3) | 3(5.3) | 8(13.8) | ||
| MV days(mean ± SD) | 1.25 ± 2.95 | 1.46 ± 3.15 | 1.34 ± 4.35 | 0.952 | |
| BPD (oxygen at 36 weeks) n (%) | 3(5.0) | 1(1.8) | 1(1.7) | 0.470 | |
| Maximum nCPAP Median (IQR) | 5(5–6) | 5(5–6) | 5(5–6) | 0.744 | |
| Surfactantn (%) | 43(71.7) | 31(54.4) | 38(65.5) | 0.144 | |
| Age at surfactantMedian (IQR) | 60(45–90) | 60(45–112.5) | 60(60–120) | 0.591 | |
| NEC Stage ≥IIA n (%) | 4(6.7) | 3(5.3) | 8(13.8) | 0.213 | |
| Sepsis n (%) | 19(31.7) | 9(15.8) | 16(27.6) | 0.123 | |
| IVH grade III or Parenchymal bleed n (%) | 2(3.3) | 1(1.8) | 0(0.0) | 0.378 | |
| Cystic PVL n (%) | 1(1.7) | 0(0.0) | 1(1.7) | 0.613 | |
| ROP with Laser n (%) | 1(1.7) | 1(1.8) | 1(1.7) | 0.999 | |
| Hospital stay Median (IQR) | 31 (16.75–45.75) | 28(17.5–40.5) | 31.5(21–51.5) | 0.748 | |
| Death n (%) | 8(13.3) | 4(7.0) | 1(1.7) | 0.067 |
SD–Standard deviation, IQR Inter quartile range, MV—Mechanical Ventilation
Values represented as mean (SD), median (IQR) or numbers (proportion);
Values represented as mean (SD), median (IQR) or numbers (proportion); analysis by
b. ANOVA test,
a. Mann-Whitney U test,
c. Chi square test or Fisher’s Exact Test